Biomarkers in clear cell renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 12, 2007, Pages 1737-1747

  George, Saby ^a   Bukowski, Ronald M ^b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Antiangiogenic therapy; Biomarker; Clear cell renal cell carcinoma; Genetic markers; Molecular markers; Predicting response; Targeted therapy; VHL mutation

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; CARBONATE DEHYDRATASE IX; GLUCOSE TRANSPORTER 1; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; LACTATE DEHYDROGENASE; PLACEBO; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HIF; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ALOPECIA; ANEMIA; ASTHENIA; BLOOD ANALYSIS; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA CELL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DESQUAMATION; DIARRHEA; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; FATIGUE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HYPERAMYLASEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOPHOSPHATASIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LABORATORY TEST; LYMPHOCYTOPENIA; MAINTENANCE DRUG DOSE; MAXIMUM PERMISSIBLE DOSE; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NAUSEA; NEPHRECTOMY; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRACTICE GUIDELINE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PRURITUS; REVIEW; SEROLOGY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; TREATMENT DURATION; TUMOR VASCULARIZATION; URINALYSIS; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 37349094385     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.12.1737     Document Type: Review

References (38)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. 349, 419-421 (2003).
3. Linehan WM, Pinto PA, Srinivasan R et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin. Cancer Res., 13, S671-S679(2007).
4. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92, 205-216 (2000).
5. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N Engl. J. Med. 356, 2271-2281 (2007).
6. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. EngL J Med. 356, 115-124 (2007).
7. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
8. Figlin R. Prognostic factors and biomarkers for renal cell carcinoma "surrogate markers". Presented at: 4th International Congress on Kidney and Bladder Cancer. Orlando, FL, USA, 27-31 March 2007.
9. Ebos JM, Bocci G, Man S et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol. Cancer Res. 2, 315-326 (2004).
10. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999).
11. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005).
12. Choueiri TK, Garcia JA, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110, 543-550(2007).
13. Beck SD, Patel MI, Snyder ME et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann. Surg. Oncol. 11, 71-77 (2004).
14. Motzer RJ, Bacik J, Mariani T et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J. Clin. Oncol. 20, 2376-2381(2002).
15. Presti JC Jr, Wilhelm M, Reuter V et al. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol. 167, 1464-1468 (2002).
16. Bukowski RM. Future directions in targeted therapy for renal carcinoma. Extended education session; biology and targeted therapy for advanced renal cell carcinoma. Presented at: American Society of Clinical Oncology, 2007 ASCO Annual Meeting. Chicago, IL, USA, June 1-5 2007.
17. Deprimo SE, Bello CL, Smeraglia J et al Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J. Transl. Med. 5, 32(2007).
18. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncot 24, 16-24 (2006).
19. Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin- 10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J. Clin. Oncol. 22, 2371-2378(2004).
20. Negrier S, Chabaud S, Escudier B et al. Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). J. Clin. Oncol. 25, S18 (2007) (Abstract 5044).
21. Teratani T, Domoto T, Kuriki K et al. Detection of transcript for brain-type fatty acid-binding protein in tumor and urine of patients with renal cell carcinoma. Urology 69, 236-240 (2007).
22. Battagli C, Uzzo RG, Dulaimi E et al. Promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Cancer Res. 63, 8695-8699 (2003).
23. Tickoo SK, Alden D, Olgac S et al. Immunohistochemical expression of hypoxia inducible factor-1α and its downstream molecules in sarcomatoid renal cell carcinoma. J. Urol. 177, 1258-1263 (2007).
24. Lidgren A, Hedberg Y, Grankvist K et al. The expression of hypoxia-inducible factor- 1 α is a favorable independent prognostic factor in renal cell carcinoma. Clin. Cancer Res. 11, 1129-1135 (2005).
25. Sharifi N, Farrar WL. Perturbations in hypoxia detection: a shared fink between hereditary and sporadic tumor formation? Med. Hypotheses 66, 732-735 (2006).
26. Lam JS, Pantuck AJ, Belldegrun AS et al. G250: a carbonic anhydrase IX monoclonal antibody. Curr. Oncol. Rep. 7, 109-115 (2005).
27. Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and K167 as predictors of survival for renal clear cell carcinoma. J. Urol. 171, 2461-2466 (2004).
28. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res., 11, 3714-3721 (2005).
29. Upton MR Parker RA, Youmans A et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J. Immunother. (1997) 28, 488-495 (2005).
30. Li G, Feng G, Gentil-Perret A et al. CA9 gene expression in conventional renal cell carcinoma: a potential marker for prediction of early metastasis after nephrectomy. Clin. Exp. Metastasis 24, 149-155 (2007).
31. Choueiri TK, Vaziri S, Rini BI et al. Use of Von-Hippel-Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). J Clin. Oncol. 25, S18 (2007) (Abstract 5012).
32. Yao M, Yoshida M, Kishida T et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J. Natl Cancer Inst. 94, 1569-1575 (2002).
33. Nagao K, Yamaguchi S, Matsuyama H et al. Allelic loss of 3p25 associated with alterations of 5q22.3 approximately q23.2 may affect the prognosis of conventional renal cell carcinoma. Cancer Genet. Cytogenet. 160,43-48 (2005).
34. Blumke K, Bilkenroth U, Schmidt U et al. Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study. Oncol Rep. 14, 895-899 (2005)..
35. Weiss RH, Borowsky AD, Seligson D et al. p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J. Urol. 177, 63-68; discussion 68-69 (2007).
36. Krambeck AE, Dong H, Thompson RH et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin. Cancer Pes. 13,1749-1756(2007).
37. Blay JY, Rossi JF, Wijdenes J et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int. J. Cancer 72, 424-430 (1997).
38. Wan X, Shen N, Mendoza A et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1α/VEGF signaling. Neoplasia 8, 394-401 (2006).